Camurus’ Buvidal® reimbursed in Sweden for the treatment of opioid dependence
- Buvidal[®] (buprenorphine) prolonged release injection receives reimbursement in Sweden from the 15 May 2020 after approval by TLV [1] Lund, Sweden — 14 May 2020 — Following a decision by the Dental and Pharmaceutical Benefits Agency, TLV , Buvidal[®] (buprenorphine) prolonged release injection has received